Rédaction Africa Links 24 with Damian Garde
Published on 2024-03-14 13:27:54
Biotech is a constantly evolving field with developments that have the potential to revolutionize healthcare and the pharmaceutical industry. Staying informed about the latest advancements and trends is crucial for professionals in the industry. One way to stay on top of the science and politics driving biotech today is by signing up for a biotech newsletter that delivers updates straight to your inbox.
One notable discussion happening today revolves around the long-awaited arrival of Humira biosimilars, and the implications they have for drug costs, insurance coverage, and pharma revenues. This discussion is being hosted by Ed Silverman, and signing up allows you to tune in and stay informed on this important topic.
In recent news, AstraZeneca announced its acquisition of the French firm Amolyt Pharma in a deal worth up to $1 billion. This acquisition includes a rare disease drug in a pivotal trial, showcasing the company’s commitment to expanding its portfolio. Additionally, the U.K.’s cost-effectiveness watchdog has not yet recommended Vertex Pharmaceutical’s CRISPR-based therapy for sickle cell disease, citing questions about the medicine’s lasting benefits for patients in its draft guidance.
Exciting developments in the treatment of brain cancer have emerged from small studies showing the promise of cell therapy. Data from patients with a deadly form of brain cancer indicate that CAR-T therapy could be a powerful treatment option. One patient in a three-person trial experienced an 18.5% reduction in tumor size in just two days, with further decreases over the following months. While more research is needed to establish CAR-T as a definitive treatment for glioblastoma multiforme, these results offer hope for a new approach in treating this aggressive cancer.
Guardant Health, a leader in liquid biopsy, reported success in its colorectal cancer screening test through a large study. While the test showed high sensitivity for detecting advanced-stage colorectal cancer, its effectiveness in identifying early-stage disease and precancerous polyps was lower. The results, published in the New England Journal of Medicine, could pave the way for FDA approval, but the test’s efficacy in clinical practice remains to be seen.
Belgian biotech firm Argenx has made significant strides with its autoimmune disorder treatment Vyvgart, generating over $1 billion in revenue last year. The company is awaiting FDA approval to expand Vyvgart’s use to include chronic inflammatory demyelinating polyneuropathy, showcasing its potential as a blockbuster drug. CEO Tim Van Hauwermeiren emphasized the transformative impact of Vyvgart on patients with autoimmune nerve disorders.
Studies related to CAR-T therapy for early-stage multiple myeloma have raised concerns among FDA reviewers. While Johnson & Johnson and Bristol Myers Squibb seek to expand their approvals, the data show more deaths among patients receiving CAR-T in the early stages of the trials. The FDA advisory committee will discuss these findings and assess the benefits and risks of expanding CAR-T treatment to earlier stages of cancer, potentially reshaping the landscape of this innovative therapy.
In conclusion, staying informed about the latest developments in biotech is essential for professionals in the field. From exciting advancements in brain cancer treatment to challenges in early-stage disease detection, the biotech industry is constantly evolving. By engaging with discussions, studies, and regulatory decisions, industry stakeholders can stay ahead of the curve and contribute to the progress of biotech innovation.
